Frontiers in Oncology · 6 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This editorial summarizes five research articles on improving radiotherapy for esophageal cancer, spanning preclinical combination approaches and clinical studies on prognostic markers and treatment sequencing. Central findings include enhanced efficacy of HuR knockdown combined with X-ray in preclinical models, improved survival with induction chemotherapy before concurrent chemoradiotherapy, and the prognostic value of the FA score and NLR in esophageal cancer patients.
This editorial reviews five research articles addressing mechanisms and strategies to improve radiosensitivity in esophageal cancer (EC). In a preclinical study, Hu et al. demonstrated that HuR knockdown combined with X-ray treatment synergistically inhibited EC cell proliferation and induced apoptosis, validated in xenograft mouse models, with HuR stabilizing Snail mRNA via 3-UTR binding. Huang et al. reported that induction chemotherapy followed by concurrent chemoradiotherapy yielded longer overall survival and progression-free survival compared with concurrent chemoradiotherapy alone in a clinical cohort. Wang et al. found that a higher pretreatment fibrinogen-albumin score was associated with shorter median overall survival in 154 ESCC patients. Another study by Wang et al. identified NLR as the best prognostic marker for locally advanced gastric cancer patients receiving adjuvant chemoradiotherapy.
